Codeine-6-glucuronide
Codeine-6-glucuronide[edit | edit source]
Codeine-6-glucuronide is a major metabolite of the opioid analgesic codeine. It is formed in the liver through the process of glucuronidation, which is a common pathway for the metabolism of many drugs. This process involves the addition of a glucuronic acid moiety to codeine, making it more water-soluble and facilitating its excretion from the body.
Formation and Metabolism[edit | edit source]
Codeine-6-glucuronide is produced by the action of the enzyme UDP-glucuronosyltransferase (UGT), specifically UGT2B7, on codeine. This reaction occurs primarily in the liver, where codeine is converted into its glucuronide form. The formation of codeine-6-glucuronide is an important step in the metabolism of codeine, as it represents a significant portion of the drug's metabolic pathway.
Pharmacological Activity[edit | edit source]
While codeine itself is a weak opioid, its metabolites, including codeine-6-glucuronide, contribute to its analgesic effects. Codeine-6-glucuronide has been shown to possess opioid activity, although its exact contribution to the overall effects of codeine is still a subject of research. It is believed to have a higher affinity for opioid receptors compared to codeine, which may enhance its analgesic properties.
Excretion[edit | edit source]
The increased water solubility of codeine-6-glucuronide allows it to be readily excreted by the kidneys. This metabolite is eliminated from the body through the urine, which is a common route for the excretion of glucuronidated compounds. The excretion of codeine-6-glucuronide is an important factor in the clearance of codeine from the body.
Clinical Significance[edit | edit source]
Understanding the metabolism of codeine to codeine-6-glucuronide is important in clinical settings, particularly in the context of pain management and opioid pharmacology. Variations in the activity of UGT enzymes can affect the levels of codeine-6-glucuronide, influencing the efficacy and safety of codeine as a medication. Additionally, genetic polymorphisms in UGT2B7 may lead to differences in drug metabolism among individuals.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
